Expression of <i>MYO18A</i> was presented as fold changes in RQ (relative quantification) mRNA levels.<h4>Results</h4>This study showed higher <i>MYO18A</i> values in patients diagnosed with grade G4 glioma among those with a shorter progression-free survival (PFS) time and those living shorter than the group average. The gene discussed is MYO18A; the disease is central nervous system cancer.